Theriva Biologics Q3 2025 cash $7.5M; raises $8M post-quarter, extends runway into Q1 2027

Theriva Biologics, Inc.

2025-Q3 EPS reported -$3.38

Cash and equivalents $7.5M at Sep 30; subsequent raises bring to $15.5M at Nov 10, funding ops into Q1 2027.
Q3 R&D expense $2.6M (-7% YoY); G&A $1.9M (-18% YoY); workforce reduction implemented Sep 30.
VIRAGE Phase 2b data for VCN-01 in metastatic PDAC presented at ESMO; planning Phase 3 discussions with EMA/FDA.
Preclinical data for next-gen oncolytic virus VCN-12 showed improved cell killing and anti-tumor immunity vs VCN-01.
Retinoblastoma Phase 2/3 trial design in progress; regulatory discussion expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.